Evidence map›Paper›PMID 38958145›Full record

ArticleMolecular genetics & genomic medicine2024

Mutational spectrum and genotype-phenotype correlation in Mexican patients with infantile-onset and late-onset Pompe disease.

Valentina Martinez-Montoya, Luz María Sánchez-Sánchez, Roberto Sandoval-Pacheco, Diana Mónica Anaya Castro, Carmen Araceli Arellano-Valdez, Carmen Amor Ávila-Rejón, Pedro Alejandro Aguilar-Juárez, Martín Espino-Pluma, Cruz Antonio González-Santillanes, Rosa Isela Martínez-Segovia and 16 more

Abstract read
In one paragraph

Article in Molecular genetics & genomic medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Valentina Martinez-MontoyaInstituto de Oftalmología Conde ABC Santa Fe, Mexico City, Mexico.ORCID https://orcid.org/0000-0001-6486-2804
Luz María Sánchez-SánchezPediatrics Service, Hospital de Especialidades UMAE 25, Instituto Mexicano del Seguro Social (IMSS), Monterrey, Nuevo León, Mexico.
Roberto Sandoval-PachecoPediatrics Emergency Service, Hospital Central Militar de Secretaría de la Defensa Nacional, Mexico City, Mexico.
Diana Mónica Anaya CastroNeurology Service, Hospital General "Dr. Ernesto Ramos Bours", Secretaría de Salud Pública, Hermosillo, Sonora, Mexico.
Carmen Araceli Arellano-ValdezPediatric Internal Medicine and Rheumatology Service, High Specialty Medical Unit, Hospital de Pediatría, Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco, Mexico.
Carmen Amor Ávila-RejónGenetics Department, Hospital de Alta Especialidad de Veracruz, Servicios de Salud de Veracruz, Xalapa, Veracruz, Mexico.
Pedro Alejandro Aguilar-JuárezNeurology Service, Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico City, Mexico.
Martín Espino-PlumaInternal Medicine Service, Clínica de Enfermedades Lisosomales, Hospital General de Zona 1, IMSS, Tlaxcala de Xicohténcatl, Tlaxcala, Mexico.
Cruz Antonio González-SantillanesRehabilitation Service, Hospital General Regional 1, IMSS, Culiacán, Sinaloa, Mexico.
Rosa Isela Martínez-SegoviaInternal Medicine Service, Hospital de Especialidades UMAE 25, Instituto Mexicano del Seguro Social (IMSS), Monterrey, Nuevo León, Mexico.
Dorian Olmos-MorfinCentro de Rehabilitación Infantil Teletón, Morelia, Michoacán, Mexico.
Ofelia Padilla-De la TorreNeurology Service, Centro Médico Nacional del Occidente, IMSS, Guadalajara, Jalisco, Mexico.
Ishar Solís-SánchezClínica de Enfermedades Neuromusculares, Centro Neurológico, Hospital Español de Veracruz, Veracruz, Veracruz, Mexico.
Mónica Vázquez-Del Mercado EspinosaRheumatology Service, Hospital Civil Dr. Juan I. Menchaca, Guadalajara, Jalisco, Mexico.
Camilo Ernesto Villarroel-CortésGenetics Service, Instituto Nacional de Pediatría, Mexico City, Mexico.
Jesús Salvador Velarde-FélixUniversidad Autónoma de Sinaloa, Culiacán, Sinaloa, Mexico.
Jaime López-ValdezGenetics Service, Centenario Hospital Miguel Hidalgo, Secretaría de Salud, Aguascalientes, Aguascalientes, Mexico.
Julio Olaiz-UrbinaPediatrics Service, Hospital General de Zona 1, IMSS, La Paz, Baja California Sur, Mexico.
Edgar Ricárdez-MarcialGenetics Service, Centro Médico Nacional La Raza, IMSS, Mexico City, Mexico.ORCID https://orcid.org/0009-0008-1274-1160
Imelda Vergara-SánchezPediatrics Neurology Service, Unidad Médica de Alta Especialidad, IMSS, Mérida, Yucatán, Mexico.
Pablo Radillo-DíazMedical Department for Rare Diseases, Sanofi-Genzyme, Mexico City, Mexico.
Ekaterina KazakovaMedical Department for Rare Diseases, Sanofi-Genzyme, Mexico City, Mexico.
Beatriz De la Fuente-CortezGenetics Service, Hospital Universitario, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico.
Luz Del Carmen Marquez-QuirózGenos Médica and Universidad Nacional Autónoma de México, Mexico City, Mexico.
Benjamín Torres-OctavoLaboratorio de Fibra Nerviosa Delgada, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Rubicel Diaz-MartinezGenetics Service, Hospital Regional de Alta Especialidad del Niño, Secretaría de Salud, Villahermosa, Tabasco, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPompe Disease (PD) is a metabolic myopathy caused by variants in the GAA gene, resulting in deficient enzymatic activity. We aimed to characterize the clinical features and related genetic variants in a series of Mexican patients.

methodsWe performed a retrospective study of clinical records of patients diagnosed with LOPD, IOPD or pseudodeficiency.

resultsTwenty-nine patients were included in the study, comprising these three forms. Overall, age of symptom onset was 0.1 to 43 years old. The most frequent variant identified was c.-32-13T>G, which was detected in 14 alleles. Among the 23 different variants identified in the GAA gene, 14 were classified as pathogenic, 5 were likely pathogenic, and 1 was a variant of uncertain significance. Two variants were inherited in cis arrangement and 2 were pseudodeficiency-related benign alleles. We identified two novel variants (c.1615 G>A and c.1076-20_1076-4delAAGTCGGCGTTGGCCTG).

conclusionTo the best of our knowledge, this series represent the largest phenotypic and genotypic characterization of patients with PD in Mexico. Patients within our series exhibited a combination of LOPD and IOPD associated variants, which may be related to genetic diversity within Mexican population. Further population-wide studies are required to better characterize the incidence of this disease in Mexican population.

Indexed as

Age of Onsetalpha-GlucosidasesGlycogen Storage Disease Type IIMutationAdolescentAdultAllelesChildChild, PreschoolFemaleGenetic Association StudiesHumansInfantMaleMexicoPhenotypealpha-GlucosidasesGAA protein, humanacid alpha‐glucosidaseGAA genemetabolic myopathyphenotype–genotype correlationPompe diseasepseudodeficiency allelerare disease

Identifiers

PMID38958145
PMCPMC11220502

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.